You are here

Article Text

Article menu
Download PDFPDF
Editorial
Towards improving clinical and patient-centred outcomes in patients with light chain amyloidosis

https://doi.org/10.1136/heartjnl-2022-321139

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Contributors KZ is the sole contributor.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests KZ reports personal fees from Eidos Therapeutics and BridgeBio Pharma, outside of the submitted work.

    • Provenance and peer review Commissioned; externally peer reviewed.

    Linked Articles

    • Heart failure and cardiomyopathies
      Prognostic importance of the 6 min walk test in light chain (AL) amyloidosis
      Oliver C Cohen Ananth Sathyanath Aviva Petrie Sriram Ravichandran Steven Law Richa Manwani Darren Foard Sajitha Sachchithanantham Shameem Mahmood Ana Martinez-Naharro Marianna Fontana Carol J Whelan Philip N Hawkins Helen J Lachmann Julian D Gillmore Ashutosh D Wechalekar
      Heart 2022; 108 1616-1622 Published Online First: 28 Jun 2022. doi: 10.1136/heartjnl-2021-320703